Immuron (ASX:IMC) has reported continued sales growth across its key markets, underscoring the expanding global footprint of its flagship over-the-counter immune supplement, Travelan.
The Australian-based, globally integrated biopharmaceutical company announced unaudited first-half results that reflect steady momentum, particularly in Australia and the United States, alongside early progress in new product and market initiatives.
Globally, Immuron recorded first-half sales of $4.2 million, representing a 5 per cent increase compared with the prior comparative period. Second-quarter sales reached $2.2 million, an 11 per cent improvement over the previous quarter, highlighting a positive acceleration in demand as the financial year progressed.
Australia remained the company’s strongest market, delivering first-half sales of $3.3 million, up 13 per cent year on year. Second-quarter sales rose to $1.7 million, also reflecting an 11 per cent quarter-on-quarter increase.
This performance was driven by growing consumer awareness of Travelan, supported by extensive digital and social media marketing campaigns, as well as same-store growth resulting from increased promotional activity and repeat purchasing. Additional contributions came from new store openings within major pharmacy banner groups and increased outbound travel to Southeast Asia. These gains were partially offset by a one-off reduction in stock holdings following the merger of Sigma Healthcare and Chemist Warehouse.
During the period, Immuron also successfully launched ProIBS in Australia ahead of schedule, despite the challenges associated with a year-end rollout. The product is now stocked by two of the country’s three largest pharmacy wholesalers and has secured listings across five banner groups. Management views the 2026 category review cycle as a meaningful opportunity to further expand distribution, expressing confidence that consumer trial will translate into sustained demand.
In the United States, first-half sales increased by 17 per cent year over year, reaching $0.9 million. Second-quarter sales grew 8 per cent quarter on quarter to $0.4 million. Growth in the U.S. market was attributed to a series of targeted marketing initiatives, including enhancements to the Travelan Amazon storefront, the establishment of dedicated U.S.-based social media channels, and increased investment in paid social, influencer-led, and organic digital marketing.
Canada presented a more mixed performance. First-half sales declined to $56,000 following a significant pipeline fill in the prior year, but momentum improved materially in the second quarter, with sales rising 191 per cent quarter on quarter to $42 thousand. This rebound followed consumer promotions launched after Travelan was placed in more than 1,000 retail locations through major pharmacy and grocery groups. Immuron said it expects continued improvement as in-store education programs, promotions, and social media activity build brand awareness. The company also confirmed that Travelan is scheduled to launch in Jean Coutu pharmacies in the third quarter of 2026, providing access to one of the largest pharmacy networks in Quebec.
Commenting on the results, Chief Executive Officer Steven Lydeamore noted that the company remains focused on building brand equity, expanding distribution, and leveraging its proprietary oral immunotherapy platform to support long-term growth across multiple markets.